Merger - Additional Information (Detail) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2022 USD ($) $ / shares shares
Business Acquisition [Line Items]
Estimated Fair value of total consideration | $	$ 103.4
Transaction costs | $	$ 1.6
Common Stock [Member]
Business Acquisition [Line Items]
Number of shares of common stock outstanding prior to the merger date	5,173,772
Shares issuable upon conversion of preferred stock [Member]
Business Acquisition [Line Items]
Number of shares of convertible preferred stock outstanding prior to merger	10,248
Common Stock Convertible Basis [Member]
Business Acquisition [Line Items]
Number of shares of Common stock as a convertible basis outstanding prior to merger	292,799
Sunesis Pharmaceuticals Inc [Member]
Business Acquisition [Line Items]
Share price | $ / shares	$ 18.62